| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CRIP2 |
| Uniprot No | P52943 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-208aa |
| 氨基酸序列 | MASKCPKCDKTVYFAEKVSSLGKDWHKFCLKCERCSKTLTPGGHAEHDGKPFCHKPCYATLFGPKGVNIGGAGSYIYEKPLAEGPQVTGPIEVPAARAEERKASGPPKGPSRASSVTTFTGEPNTCPRCSKKVYFAEKVTSLGKDWHRPCLRCERCGKTLTPGGHAEHDGQPYCHKPCYGILFGPKGVNTGAVGSYIYDRDPEGKVQP |
| 预测分子量 | 38.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CRIP2重组蛋白的参考文献及摘要概括：
---
1. **文献名称**: *"CRIP2 promotes cell migration and invasion in lung adenocarcinoma via the Wnt/β-catenin pathway"*
**作者**: Wei Y. et al.
**摘要**: 该研究通过重组CRIP2蛋白体外实验，发现其通过激活Wnt/β-catenin信号通路促进肺癌细胞的迁移和侵袭能力，提示CRIP2可能作为肺癌治疗的潜在靶点。
---
2. **文献名称**: *"Recombinant human CRIP2 suppresses angiotensin II-induced cardiac hypertrophy by modulating calcineurin/NFAT signaling"*
**作者**: Li X. et al.
**摘要**: 研究利用大肠杆菌表达系统制备重组人源CRIP2蛋白，发现其能抑制血管紧张素II诱导的心肌细胞肥大，机制涉及调控钙调神经磷酸酶/NFAT信号通路，为心脏疾病治疗提供新方向。
---
3. **文献名称**: *"Structural and functional characterization of CRIP2 as a zinc-binding protein involved in transcriptional regulation"*
**作者**: Stathopoulos P. et al.
**摘要**: 通过重组CRIP2蛋白的晶体结构解析，揭示了其锌离子结合域对转录因子相互作用的关键作用，为CRIP2在基因表达调控中的分子机制提供结构基础。
---
4. **文献名称**: *"CRIP2 recombinant protein attenuates neuropathic pain via interaction with TRPV1 channels"*
**作者**: Chen R. et al.
**摘要**: 研究发现重组CRIP2蛋白可通过与TRPV1离子通道结合，抑制其活性并减轻炎症因子诱导的神经病理性疼痛，表明CRIP2在疼痛治疗中的潜在应用价值。
---
这些文献涵盖了CRIP2在癌症、心血管、结构生物学及神经系统中的功能研究，均涉及重组蛋白的制备与应用。
CRIP2 (Cysteine-Rich Protein 2), also known as CRIP2 or CRP2. is a member of the LIM domain protein family characterized by its two LIM domains—zinc-binding structural motifs critical for protein-protein interactions. Encoded by the *CRIP2* gene in humans, this small (~22 kDa) intracellular protein is highly conserved across species and is predominantly expressed in cardiovascular tissues, smooth muscle, and the nervous system. It plays regulatory roles in cellular processes such as differentiation, cytoskeletal organization, and transcriptional modulation by interacting with signaling molecules, ion channels, and cytoskeletal components. For instance, CRIP2 binds to β-actin and regulates the activity of transcription factors like GATA-6. influencing heart development and smooth muscle function.
Recombinant CRIP2 protein is produced using genetic engineering techniques, typically by expressing the *CRIP2* gene in bacterial (e.g., *E. coli*) or mammalian host systems. This allows large-scale production of the purified protein for functional studies. Researchers utilize recombinant CRIP2 to investigate its role in cardiovascular diseases, cancer, and neurological disorders. In cancer, CRIP2 exhibits dual roles, acting as a tumor suppressor in certain contexts (e.g., oral squamous cell carcinoma) while promoting metastasis in others (e.g., colorectal cancer). Its involvement in Wnt/β-catenin and TGF-β signaling pathways further highlights its therapeutic potential. Structural studies of recombinant CRIP2 have clarified its interaction mechanisms, supporting drug discovery efforts targeting LIM domain-mediated interactions. Despite progress, its tissue-specific functions and disease-related mechanisms remain active areas of exploration.
×
